SCHEMBL22372184

SCHEMBL22372184

O=C(NCC1CC1)c1c[nH]nn1

nearest known ligand 0.45

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.45
CNR1 P21554 1/20 0.42
MLLT1 Q03111 1/20 0.41
GLS O94925 5/20 0.40
NAMPT P43490 1/20 0.40
ALDH1A1 P00352 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5523261 0.83 HIF1A (0.44) HIF1A
SCHEMBL5523265 0.83 HIF1A (0.44) HIF1A
SCHEMBL14331908 0.80 KDM4E (0.62) GLSNAMPTKDM4E
SCHEMBL30163145 0.76 MEN1 (0.39) CNR1ALDH1A1KDM4E
SCHEMBL9957276 0.76 CNR1 (0.38) CNR1ALDH1A1KDM4E
SCHEMBL19691216 0.75 SMYD3 (0.42) MLLT1
SCHEMBL22372103 0.74 HIF1A (0.48) HIF1ACNR1MLLT1ALDH1A1KDM4E
SCHEMBL22372167 0.74 CNR1 (0.45) HIF1ACNR1MLLT1ALDH1A1TDP1
SCHEMBL1808230 0.73
SCHEMBL4553284 0.72 ROCK2 (0.50) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264138-B2 Process for the preparation of microbiocidal oxadiazole derivatives SYNGENTA CROP PROTECTION AG (CH) 2025-04-01 US disclosed
US-20220194907-A1 PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2022-06-23 US disclosed
US-11358957-B2 Microbiocidal oxadiazole derivatives SYNGENTA PARTICIPATIONS AG (CH) 2022-06-14 US disclosed
US-20200277287-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2020-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12264138-B2 Process for the preparation of microbiocidal oxadiazole derivatives CYP51A1, MPO, NOX5 HIF1A 2242/4885CNR1 3686/4885MLLT1 4213/4885
US-20200277287-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES PRF1, NOX1, ARG2 HIF1A 3545/4885CNR1 1622/4885MLLT1 3898/4885
US-11358957-B2 Microbiocidal oxadiazole derivatives PRF1, NOX1, ARG2 HIF1A 3545/4885CNR1 1622/4885MLLT1 3898/4885
US-20220194907-A1 PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES CYP51A1, MPO, NOX5 HIF1A 2242/4885CNR1 3686/4885MLLT1 4213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.